灵芝多糖对肺癌患者血清淋巴细胞活化的抑制作用

The effects of Ganoderma lucidum polysaccharides on serum of lung cancer patients suppressing lymphocyte activation

目的 研究灵芝多糖对肺癌患者血清淋巴细胞活化抑制的作用.方法 将含有终浓度为0、0.2、 0.8、3.2、12.8 mg/L 灵芝多糖的肺癌患者血清与肺癌患者的淋巴细胞进行体外培养，以健康人血清代替肺癌患者 血清为对照。采用四甲基偶氮唑盐（MTT）比色法检测淋巴细胞的增殖活性，用流式细胞仪检测淋巴细胞CD69 的表达。结果 在肺癌患者血清作用下，植物血凝素（PHA）诱导的淋巴细胞增殖活性〔吸光度（A ）值〕和CD69 阳性表达率以未加灵芝多糖的肺癌血清组最低，健康对照组最高。与健康对照组比较，未加灵芝多糖的肺癌血 清组淋巴细胞增殖活性（0.654±0.029 比1.213±0.106）、CD69 阳性率〔（33.04±16.76）% 比（74.18±12.16）%〕均 明显降低（均P ＜0.01）。不同浓度的灵芝多糖均可使淋巴细胞增殖活性和CD69 阳性率有所升高，且随浓度增 大升高更明显。与未加灵芝多糖的肺癌血清组比较，浓度为0.2、0.8、3.2、12.8 mg/L 灵芝多糖组的淋巴细胞增殖 活性均明显升高（分别为0.759±0.053、0.865±0.091、0.935±0.062、1.080±0.097，均P ＜0.01）；浓度为3.2 mg/L、 12.8 mg/L 灵芝多糖组CD69 阳性率均明显增加〔分别为（56.97±15.43）%、（67.82±10.85）%，均P ＜0.01〕，浓度 为0.2 mg/L、0.8 mg/L 灵芝多糖组无明显变化（均P ＞0.05），其中浓度为12.8 mg/L 灵芝多糖组CD69 阳性率已 接近健康对照组，差异无统计学意义（P ＞0.05）. 结论 灵芝多糖具有拮抗肺癌患者血清抑制淋巴细胞活化 的作用.

Objective To study the effects of Ganoderma lucidum polysaccharides （GLPs） on serum of lung cancer patients suppressing the activation of lymphoeytes. Methods The serums of lung cancer patients containing GLPs at the final concentrations of 0, 0.2, 0.8, 3.2 and 12.8 mg/L were used to culture the lymphocytes of the patients in vitro and the controls were set up using healthy serum instead of lung cancer patient＇s serum. The methyl thiazlyl tetrazolium （MTT） assay was used to detect the proliferation of the lymphocytes and the flow cytometry was used to determine the expression of CD69 on the lymphocytes. Results Under the action of the serum of lung cancer patients, the proliferation ~ absorbance （A） value） and expression rate of CD69 on lymphoeytes induced by phytohemagglutinin （PHA） were the lowest in the group of serum of lung cancer patients without the addition of GLPs, and the highest in the healthy serum control group. Compared with the healthy control group, the proliferation （0.654±0.029 vs. 1.213±0.106） and the expression rate of CD69 [（33.04±16.76）% vs. （74.18±12.16）%] in the group of serum of lung cancer patients without the addition of GLPs were obviously lower （both P〈0.01 ）. All of the GLPs at different concentrations increased the proliferation and expression rate of CD69 and along with the increase in concentration of GLPs, the proliferation and the expression rate of CD69 were elevated more obviously. Compared with the group of serum of lung cancer patients without GLPs, the proliferation in lymphocytes in groups of GLPs at concentrations of 0.2,0.8, 3.2 and 12.8 mg/L were increased remarkably（0.759±0.053,0.865±0.091, 0.935±0.062, 1.080±0.097, respectively, all P〈0.01 ） ; the expression rates of CD69 in group of GLPs at concentrations of 3.2 and 12.8 mg/L were increased significantly [ （ 56.97± 15.43） %, （67.82± 10.85 ） %, both P〈0.01 ], in which the group of GLPs at concentration of 12.8 mg/L was already approximately similar to that in the healthy control group （P〉 0.05）, and the difference between the groups of GLPs at concentrations of 0.2 and 0.8 mg/L did not have any statistical significance （both P〉0.05）. Conclusion GLPs have the antagonistic effects on the suppression of the serum of lung cancer patients on lymphocyte activation.